Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 37Active not recruiting 30Recruiting 24Terminated 23Unknown 7Withdrawn 6Not yet recruiting 4Suspended 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Genitourinary 6Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Melanoma 11Triple Negative Breast Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Neoplasms 7Head and Neck Neoplasms 7Multiple Myeloma 6Carcinoma, Transitional Cell 6Carcinoma, Renal Cell 6Pancreatic Neoplasms 5Lung Neoplasms 4Recurrence 3Prostatic Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Sarcoma 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Kidney Neoplasms 2Inflammatory Breast Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Urothelial Cancer 1Thyroid Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Spinocerebellar Degenerations 1

Interventions

pembrolizumab 6Sunitinib 5Bevacizumab 4Sorafenib 3Radiotherapy 3Radiosurgery 3Nivolumab 3Magnetic Resonance Spectroscopy 3Interleukin-2 3Cyclophosphamide 3Axitinib 3tivozanib 2fludarabine phosphate 2durvalumab 2avelumab 2atezolizumab 2Peripheral Blood Stem Cell Transplantation 2Optical Imaging 2Nephrectomy 2Gene Expression Profiling 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2tremelimumab 1temsirolimus 1siltuximab 1sargramostim 1pazopanib 1pamiparib 1milademetan 1lenvatinib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Renal Cell × pembrolizumab × Clear all
NCT06361810 2025-08-19

PSMA Therapy and Immunotherapy in Kidney Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Withdrawn
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07011849 2025-08-13

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT04555603 2023-11-21

Axitinib Therapy Management Study

Pfizer

Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT05263609 2022-08-02

Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

University of Oklahoma

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT03189186 2021-04-05

Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas

University of California, Irvine

Phase 1 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03111901 2019-07-12

UVA-AM-002

University of Virginia

Phase 1/2 Withdrawn
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡